Concepedia

Cameron Douglas

CD

Statistics

Publications

33

Citations

4.3K

H-Index

25

Active since

1987

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

University of California, Los Angeles

Harvard University

The University of Texas MD Anderson Cancer Center

Johns Hopkins University

Cameron Douglas is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in life sciences, microbiology, and antifungal agents.

Publications per year

1987–2024

33

Publications

33

Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical <i>Candida</i> sp. Isolates

S. Park, Rosemarie Kelly, Jennifer Nielsen Kahn et al. · Antimicrobial Agents and Chemotherapy · 2005 · 432 citations

, , +17

The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-beta-D-glucan synthase.

Cameron Douglas, F Foor, J A Marrinan et al. · Proceedings of the National Academy of Sciences · 1994 · 402 citations

, , +17

Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors

Cameron Douglas, Joseph A. D'Ippolito, G.-J. Shei et al. · Antimicrobial Agents and Chemotherapy · 1997 · 339 citations · Full text

, , +17

Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase

Martha Kurtz, I. Brent Heath, J A Marrinan et al. · Antimicrobial Agents and Chemotherapy · 1994 · 322 citations · Full text

, , +17

Discovery of Novel Antifungal (1,3)-β- <scp>d</scp> -Glucan Synthase Inhibitors

Janet C. Onishi, M. Meinz, John R. Thompson et al. · Antimicrobial Agents and Chemotherapy · 2000 · 319 citations · Full text

, , +17

1–5 of 33